Search company, investor...

ACT Biotech

actbiotech.com

Founded Year

2008

Stage

Acquired | Acquired

Total Raised

$12M

Valuation

$0000 

About ACT Biotech

ACT Biotech aims to bring therapies to bear in managing cancer, especially in underserved disease sectors where patient need is acute. Per the company, ACT has launched an aggressive, focused development strategy designed to accelerate delivery of therapeutic tools to respond to the needs of cancer patients.

Headquarters Location

717 Market Street Suite 650

San Francisco, California, 94103,

United States

415-230-3900

Missing: ACT Biotech's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: ACT Biotech's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing ACT Biotech

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

ACT Biotech is included in 2 Expert Collections, including Cancer.

C

Cancer

1,179 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

B

Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Latest ACT Biotech News

Government Authorities Approve Joint Venture for Cardiac Rhythm Management Business in China

May 28, 2014

Week in Review: Eddingpharm Buys ACT Biotech Assets for Million The Shanghai-based joint-venture company, named MicroPort Sorin CRM (Shanghai) Co. Ltd, is scheduled to commence operations in June. MicroPort holds 51 percent stake of the new firm, while Sorin Group holds the remaining 49 percent interest. The joint venture was approved by the Shanghai Municipal Commission of Commerce (COFCOM) on May 6. The joint venture will allow MicroPort and Sorin to collaborate on the import, sale and service of Sorin’s CRM devices in Greater China and accelerate the R&D and manufacturing of the local CRM products for the Chinese market. About MicroPort MicroPort Scientific Corporation is a leading medical device company publicly listed on the main board of Hong Kong (HK853). The Group focuses on innovating, manufacturing, and marketing high-quality and yet still affordable high-end medical devices globally. With a diverse portfolio of products now being used at an average rate of one for every 30 seconds in over 2,000 major hospitals throughout China and over 20 other countries, MicroPort maintains operations in a wide range of business segments including Cardiovascular Devices, Orthopedic Devices, Electrophysiological Devices, Endovascular Devices, Neurovascular Devices, Surgical Management, Diabetes Care and Endocrinal Management, and others. MicroPort is dedicated to becoming a leading global enterprise capable of providing the best and most affordable medical products and technologies to patients throughout the world. For more information, please refer to www.microport.com About Sorin Group Sorin Group (Reuters Code: SORN.MI), is a global medical device company and a leader in the treatment of cardiovascular diseases. The Company develops, manufactures and markets medical technologies for cardiac surgery and for the treatment of cardiac rhythm disorders. With 3,750 employees worldwide, the Company focuses on two major therapeutic areas: Cardiac Surgery (cardiopulmonary products for open heart surgery and heart valve repair or replacement products) and Cardiac Rhythm Management (pacemakers, defibrillators, cardiac resynchronization devices). Every year, over one million patients are treated with Sorin Group devices in more than 80 countries. For more information, please refer to www.sorin.com Jonathan Chen, Tel: (86)(21) 38954600 Senior Vice President, International

ACT Biotech Frequently Asked Questions (FAQ)

  • When was ACT Biotech founded?

    ACT Biotech was founded in 2008.

  • Where is ACT Biotech's headquarters?

    ACT Biotech's headquarters is located at 717 Market Street, San Francisco.

  • What is ACT Biotech's latest funding round?

    ACT Biotech's latest funding round is Acquired.

  • How much did ACT Biotech raise?

    ACT Biotech raised a total of $12M.

  • Who are the investors of ACT Biotech?

    Investors of ACT Biotech include Eddingpharm and NGN Capital.

  • Who are ACT Biotech's competitors?

    Competitors of ACT Biotech include Molmed, Raptor Pharmaceutical Corp., Cellerant Therapeutics, Crux Biomedical, Merrimack Pharmaceuticals and 12 more.

Compare ACT Biotech to Competitors

A
American Stem Cell

ASC is a privately held biotechnology company dedicated to the development and commercialization of enabling technologies to enhance and expand the therapeutic potential of stem cell therapies. The key technology platforms (ASC-101 and ASC-201) are designed to improve the homing and engraftment of stem cells to target organs and increase their therapeutic potential for cancer patients. Additionally, these platforms have the potential to enhance stem cell treatment of inflammation from chemotherapy/radiation, solid tumors, autoimmune diseases, and ischemic diseases including myocardial infarction and stroke. ASC has strategic partnerships with medical research institutions including the University of Texas M.D. Anderson Cancer Center, the Oklahoma Medical Research Foundation, University of California, the Burnham Institute, Indiana University, Rush Presbyterian and VidaCord Technologia Biomedica.

E
Epeius Biotechnologies

Scientists at Epeius Biotechnologies have developed a targeted delivery system (TDS) that can transport genes or other therapeutic agents directly to diseased areas in the body. This pathotropic, or disease-seeking, technology has enabled the company to develop Rexin-G, a tumor-targeted, injectable gene delivery system that has demonstrated remarkable safety and single-agent efficacy in clinical trials internationally. Rexin-G is currently in clinical trials for pancreatic cancer in the U.S. ƒƒ‚ƒš‚" where it has achieved FDA orphan drug status ƒƒ‚ƒš‚" and has accelerated approval in the Philippines for the treatment of all solid tumors that are resistant to standard chemotherapy. The company's international clinical outreach with Rexin-G has enabled us to expedite further demonstrations that Rexin-G is highly active in a broad spectrum of chemo-resistant tumor types with efficacy and excellent safety profiles. The company are a biopharmaceutical company focused on expanding the therapeutic utility and commercialization of the company's pathotropic approach to disease treatment through internal development and commercialization of the company's oncology products and cancer vaccines, and through strategic partnerships in additional areas of oncology, immunology, cardiovascular, ocular, and wound healing applications, precision targeted diagnostics, and stem cell technologies.

T
Timi3 Systems

Timi3 Systems, Inc., a biotechnology company, develops a non-invasive transcutaneous ultrasound system for the treatment of patients experiencing an acute myocardial infarction or heart attack. The company specializes in the non-invasive delivery of thrombolytic drugs that hasten the dissolution of thrombus during a myocardial infarction. Timi3 Systems, Inc. was founded in 1999 and is based in Santa Clara, California.

C
CELLective Dx Corporation

CELLective Dx is an early-stage company developing a new generation of diagnostic tools for cancer based on analysis of CTCs directly from a patient's blood. Our novel proprietary technologies combine microfluidics, flow dynamics, cell biology, molecular biology, biochemistry, and surface chemistry to capture and analyze rare CTCs in blood more rapidly and effectively than other current technologies. CELLective Dx is developing simple, rapid, blood-based cancer tests that will provide physicians and patients with accurate and individualized clinical information on disease status, treatment selection, and treatment response that will dramatically improve the clinical management of cancer.

A
Adriacell

Adriacell s.r.l is a biotech company focused in oncology pharmaceuticals founded in Basovizza (Trieste) in March 2004 by Prof. Christian Kuehne, an Austrian citizen.nThe company is leveraging its efforts and scientific expertise to successfully solve important worldwide health problems; in particular, it has been striving to develop a new class of anti-tumour therapeutics and to create a series of powerful diagnostics for the early detection of cancer progression. The company is also developing new and highly powerful delivery solutions through small molecules as the basis for a new class of anti-infective drugs.nAdriaCell owns a patented system that can be used for the study of events subsequent to DNA double strand breaks, a very important issue for cancer research and diagnostics. Adriacell is currently evaluating a new class of therapeutics for cancer; its main lead compound is about to enter the pharmacokinetic and toxicology phases.nAdriacell Vision is to become a leader biotech drug development company concentrated in the development of solutions (treatment and diagnostics) for tumours characterized by low probability of survival for patients and of anti infective agents. Thanks to future developments in research and test activities Adriacell solutions will hopefully become useful in a wider range of pathologies.

B
Bolder BioTechnology

Bolder BioTechnology, Inc. uses advanced protein engineering technologies to create human protein pharmaceuticals with enhanced therapeutic properties. Most protein pharmaceuticals are rapidly eliminated by the body, which limits their effectiveness and requires that they be administered by frequent, often daily, injection. The company's products are designed to last longer in the body, which aims to allow them to be administered less frequently, e.g., once per week to once per month, and maximizes their therapeutic benefits to patients. Company scientists combine protein structure/function information with targeted protein modification technologies to rationally design long-acting protein pharmaceuticals that, in many cases, are 10-100-fold more potent than competing products prepared using non-targeted protein modification technologies. Bolder BioTechnology has a robust pipeline of products in preclinical development, including products for the treatment of hematological and endocrine disorders, cancer and infectious disease. The company intend to commercialize these products independently and through strategic alliances with corporate partners.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.